Belimumab
Brand name: Benlysta
Rank #216 of 500 drugs by total cost
$63.4M
Total Cost
13,386
Total Claims
$63.4M
Total Cost
566
Prescribers
$4,737
Cost per Claim
235
Beneficiaries
13,636
30-Day Fills
$112K
Avg Cost/Provider
24
Avg Claims/Provider
About Belimumab
Belimumab (sold as Benlysta) was prescribed 13,386 times by 566 Medicare Part D providers in 2023, costing the program $63.4M. At $4,737 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 213 | Risperidone Microspheres (Risperdal Consta) | $64.8M | 47,567 |
| 214 | Venlafaxine Hcl (Venlafaxine Hcl) | $64.7M | 2,187,710 |
| 215 | Canagliflozin (Invokana) | $63.7M | 66,550 |
| 216 | Belimumab (Benlysta) | $63.4M | 13,386 |
| 217 | Collagenase Clostridium Hist. (Santyl) | $63.3M | 70,641 |
| 218 | Insulin Lispro Protamin/Lispro (Humalog Mix 75-25 Kwikpen) | $62.8M | 60,873 |
| 219 | Furosemide (Furosemide) | $62.3M | 9,788,207 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology